Wellington Management Group LLP Cuts Position in Haemonetics Co. (NYSE:HAE)

Wellington Management Group LLP cut its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 6.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 3,940,224 shares of the medical instruments supplier's stock after selling 261,341 shares during the period. Wellington Management Group LLP owned about 7.84% of Haemonetics worth $307,653,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. Whittier Trust Co. acquired a new position in shares of Haemonetics during the 4th quarter worth about $62,000. Parkside Financial Bank & Trust increased its stake in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares during the last quarter. KBC Group NV raised its holdings in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Haemonetics in the third quarter valued at approximately $204,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Needham & Company LLC reduced their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. JMP Securities lowered their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Trading Down 2.3 %

Shares of Haemonetics stock traded down $1.42 during mid-day trading on Friday, hitting $60.80. The stock had a trading volume of 1,019,545 shares, compared to its average volume of 671,984. The firm has a 50-day moving average of $65.01 and a two-hundred day moving average of $74.25. The firm has a market cap of $3.05 billion, a P/E ratio of 23.94, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.